Carlo Selmi

Full Professor

Internal Medicine

Director of the Residency School of Emergency Medicine, Humanitas University

E-mail

carlo.selmi@hunimed.eu
Sito

www.humanitas.it/medici/carlo-francesco-selmi

Dr. Selmi received his MD in 1998 and his PhD in Internal Medicine in 2002, both from the University of Milan. He was appointed Assistant Professor by the same University for Internal Medicine in 2006 and for Rheumatology between 2011 and 2019. As of 2019, he is Associate Professor of Internal Medicine at Humanitas University in Milan. In 2004 he was awarded the Young Researcher prize by the Italian Society of Internal Medicine and in 2005 the Young Investigator Award by the Aesku-Kipp Foundation. Dr. Selmi was a post-doctoral researcher between august 2001 and december 2004 at the Division of Rheumatology, Allergy, and Clinical Immunology of the University of California, Davis School of Medicine. Between July 2005 and decemver 2014, he was appointed Assistant Adjunct Professor of Medicine by the same Division at UC Davis.

Carlo Selmi currently leads the Rheumatology and Clinical Immunology Unit at Humanitas research hospital. At Humanitas he leads a young group of physician scientists with wide research and clinical expertise, including periods working at foreign institutions. The team holds dedicated clinics for rheumatoid arthritis, spondiloarthritis, connective tissue disease with dedicated clinics for systemic sclerosis and systemic lupus erythematosus, and is active in articular ultrasound, videocapillaroscopy, arthrocenthesis and intra-articular injections.

He has coauthored over 300 peer-reviewed publications with a Scopus H index of 55 and a total impact factor exceeding 2000.

His research track is dedicated to organ-specific and systemic autoimmune and chronic inflammatory diseases, including the clinical epidemiology and pathogenetic mechanisms of autoimmune liver disease, connective tissue disease (particularly systemic sclerosis), and psoriatic arthritis. His work has been funded by the National Institutes of Health, American Liver Foundation, American Scleroderma Foundation, Italian Ministry of Health, Italian Ministry of Foreign Affairs, and the Lilly Research Foundation.

SELMI C., Ceribelli A., Generali E., Scirè C.A., Alborghetti F., Colloredo G., Porrati L., Achenza M.I., De Santis M., Cavaciocchi F., Massarotti M., Isailovic N., Paleari V., Invernizzi P., Matthias T., Zucchi A., Meroni P.L. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev. 2016.
Generali E., Ceribelli A., Stazi M.A., SELMI C. Lessons learned from twins in autoimmune and chronic inflammatory diseases. J Autoimmun. 2017
Favalli E.G., SELMI C., Becciolini A., Biggioggero M., Ariani A., Santilli D., Fusaro E., Parisi S., Massarotti M., Marchesoni A., Meroni P.L. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: A multi-center retrospective analysis. Arthritis Care Res (Hoboken).
Rizzetto L, Fava F, Tuohy KM, SELMI C. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex. J Autoimmun. 2018
Generali E, Carrara G, Kallikourdis M, Condorelli G, Bortoluzzi A, Scirè CA, SELMI C. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int. 2019